Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kaur, Sukhbir ^a   Soto Pantoja, David R ^a   Stein, Erica V ^a,b   Liu, Chengyu ^c   Elkahloun, Abdel G ^d   Pendrak, Michael L ^a   Nicolae, Alina ^a   Singh, Satya P ^e   Nie, Zuqin ^a   Levens, David ^a   Isenberg, Jeffrey S ^a,f   Roberts, David D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; CD47 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CYTOLOGY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; ANTIGENS, CD47; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; MICE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; STEM CELLS; THROMBOSPONDIN 1; TRANSCRIPTION FACTORS;

EID: 84876587975     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01673     Document Type: Article

References (73)

1. Matozaki, T., Murata, Y., Okazawa, H. & Ohnishi, H. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 19, 72-80 (2009).
2. Roberts, D. D., Miller, T. W., Rogers, N. M., Yao, M. & Isenberg, J. S. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress. Matrix Biol. 31, 162-169 (2012).
3. Frazier, W. A., Isenberg, J. S., Kaur, S. & Roberts, D. D. in UCSD Nature Molecule Pages (2010). doi:10.1038/mp.a002870.01.
4. Isenberg, J. S. et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109, 1945-1952 (2007). (Pubitemid 46348191)
5. Thakar, C. V. et al. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 115, 3451-3459 (2005). (Pubitemid 43121833)
6. Isenberg, J. S. et al. Treatment of ischemia/reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery 144, 752-761 (2008).
7. Isenberg, J. S. et al. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am. J. Pathol. 173, 1100-1112 (2008).
8. Maxhimer, J. B. et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci. Transl. Med. 1, 3ra7 (2009).
9. Bras, M. et al. Drp1 mediates caspase-independent type III cell death in normal and leukemic cells. Mol Cell Biol 27, 7073-7088 (2007). (Pubitemid 47549746)
10. Lamy, L. et al. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 178, 5930-5939 (2007). (Pubitemid 46674390)
11. Frazier, E. P. et al. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 30, 154-161 (2011).
12. Kang, R., Zeh, H. J., Lotze, M. T. & Tang, D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18, 571-580 (2011).
13. Soto-Pantoja, D. R. et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8, 1628-1642 (2012).
14. Soto-Pantoja, D. R., Ridnour, L. A., Wink, D. A. & Roberts, D. D. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep 3, 1038 (2013).
15. Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054 (2000).
16. Kim, M. J. et al. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 29, 28-34 (2008). (Pubitemid 351733217)
17. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
18. Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106, 14016-14021 (2009).
19. Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
20. Chao, M. P. et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71, 1374-1384 (2011).
21. Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109, 6662-6667 (2012).
22. Zhao, X. W. et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108, 18342-18347 (2011).
23. Soto-Pantoja, D. R., Miller, T. W., Frazier, W. A. & Roberts, D. D. Inhibitory signaling through signal regulatory protein-alpha is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci USA 109, E2842 (2012).
24. Zhao, X. W.,Kuijpers, T. W.&van den Berg, T. K. Is targeting of CD47-SIRPalpha enough for treating hematopoietic malignancy? Blood 119, 4333-4334.
25. Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
26. Nie, Z. et al. c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells. Cell 151, 68-79 (2012).
27. Kurz, D. J., Decary, S., Hong, Y.&Erusalimsky, J. D. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113 (Pt 20), 3613-3622 (2000).
28. Wang, C., Lisanti, M. P. & Liao, D. J. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 10, 57-67 (2011).
29. Alexandrova, N. et al. The N-terminal domain of c-Myc associates with alphatubulin and microtubules in vivo and in vitro. Mol Cell Biol 15, 5188-5195 (1995).
30. Pusztaszeri, M. P., Seelentag, W. & Bosman, F. T. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 54, 385-395 (2006).
31. Kim, K. S. et al. Self-renewal induced efficiently, safely, and effective therapeutically with one regulatable gene in a human somatic progenitor cell. Proc Natl Acad Sci USA 108, 4876-4881 (2011).
32. Varlakhanova, N. V. et al. myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation 80, 9-19 (2010).
33. Okita, K. & Yamanaka, S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 366, 2198-2207 (2011).
34. Keramari, M. et al. Sox2 is essential for formation of trophectoderm in the preimplantation embryo. PLoS One 5, e13952 (2010).
35. Sundararaman, B. et al. Asymmetric chromatid segregation in cardiac progenitor cells is enhanced by Pim-1 kinase. Circ Res 110, 1169-1173 (2012).
36. Pine, S. R., Ryan, B. M., Varticovski, L., Robles, A. I. & Harris, C. C. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci USA 107, 2195-2200 (2010).
37. Panopoulos, A. D. et al. Rapid and highly efficient generation of induced pluripotent stem cells from human umbilical vein endothelial cells. PLoS One 6, e19743 (2011).
38. Medici, D. et al. Conversion of vascular endothelial cells into multipotent stemlike cells. Nat Med 16, 1400-1406 (2010).
39. Rehman, J., Li, J., Orschell, C. M. & March, K. L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169 (2003). (Pubitemid 36297209)
40. Itskovitz-Eldor, J. et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 6, 88-95 (2000).
41. Bhattacharya, B. et al. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood 103, 2956-2964 (2004). (Pubitemid 38451667)
42. Sheridan, S. D., Surampudi, V. & Rao, R. R. Analysis of embryoid bodies derived from human induced pluripotent stem cells as a means to assess pluripotency. Stem Cells Int 2012, 738910 (2012).
43. Smith, K. P., Luong, M. X. & Stein, G. S. Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol 220, 21-29 (2009).
44. Genovesi, E. V. et al. In vitro induction of swine peripheral blood monocyte proliferation by the fibroblast-derived murine hematopoietic growth factor CSF-1. Vet Immunol Immunopathol 23, 223-244 (1989). (Pubitemid 20091415)
45. Tompkins, D. H. et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One 4, e8248 (2009).
46. Faustman, D. L. Regenerative medicine: Stem cell research turns to the spleen. Discov Med 5, 447-449 (2005).
47. Faustman, D. L. & Davis, M. Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders. Int J Biochem Cell Biol 42, 1576-1579 (2010).
48. Isenberg, J. S. et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 100, 712-720 (2007). (Pubitemid 46594886)
49. Reinhold, M. I., Green, J. M., Lindberg, F. P., Ticchioni, M. & Brown, E. J. Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28. Int Immunol 11, 707-718 (1999). (Pubitemid 29237762)
50. Zhou, L., Isenberg, J. S., Cao, Z. & Roberts, D. D. Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1. Oncogene 25, 536-545 (2006). (Pubitemid 43164464)
51. Li, Z. et al. Interactions of thrombospondins with a4b1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 157, 509-519 (2002). (Pubitemid 34839813)
52. O'Connell, B. C. et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278, 12563-12573 (2003). (Pubitemid 36800246)
53. Huber, K. R. et al. Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignantmurine cells. Br J Cancer 59, 714-718 (1989). (Pubitemid 19148531)
54. Kanda, K., Hu, H. M., Zhang, L., Grandchamps, J. & Boxer, L. M. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J Biol Chem 275, 32338-32346 (2000).
55. Lindgren, A. G. et al. Loss of Pten causes tumor initiation following differentiation of murine pluripotent stem cells due to failed repression of Nanog. PLoS One 6, e16478 (2011).
56. Vazquez-Martin, A. et al. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep 2, 964 (2012).
57. Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11, 268-277 (2011).
58. Hayashi, H., Sakai, K., Baba, H. & Sakai, T. Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy via TGF-beta1 activation in mice. Hepatology 55, 1562-1573 (2012).
59. Smadja, D. M. et al. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 31, 551-559 (2011).
60. Shaked, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101-111 (2005). (Pubitemid 40126386)
61. Ii, M. et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 98, 697-704 (2006).
62. Janz, A., Sevignani, C., Kenyon, K., Ngo, C. V. & Thomas-Tikhonenko, A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 28, 2268-2275 (2000). (Pubitemid 30639360)
63. Zhou, L. et al. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 70, 8199-8210 (2010).
64. Mawby, W. J., Holmes, C. H., Anstee, D. J., Spring, F. A. & Tanner, M. J. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 304, 525-530 (1994). (Pubitemid 24368233)
65. Isenberg, J. S. et al. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 27, 2582-2588 (2007). (Pubitemid 350158909)
66. Raman, P., Harry, C., Weber, M., Krukovets, I. & Stenina, O. I. A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol 31, 634-642 (2011).
67. Bauer, P. M. et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 93, 682-693 (2012).
68. Simons, B. D. & Clevers, H. Strategies for homeostatic stem cell self-renewal in adult tissues. Cell 145, 851-862 (2011).
69. Kaur, S. et al. Thrombospondin-1 inhibits vascular endothelial growth factor receptor-2 signaling by disrupting its association with CD47. J Biol Chem 285, 38923-38932 (2010).
70. Lawler, J. et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101, 982-992 (1998). (Pubitemid 28125276)
71. Lindberg, F. P. et al. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 274, 795-798 (1996). (Pubitemid 26398263)
72. Kaur, S. et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 286, 14991-15002 (2011).
73. Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4, 1798-1806 (2009).